Prosecution Insights
Last updated: April 19, 2026
Application No. 18/263,079

URINARY CATHETER KIT

Non-Final OA §102§103
Filed
Jul 26, 2023
Examiner
HALL, DEANNA K
Art Unit
3783
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
B. Braun Avitum AG
OA Round
1 (Non-Final)
76%
Grant Probability
Favorable
1-2
OA Rounds
3y 3m
To Grant
91%
With Interview

Examiner Intelligence

Grants 76% — above average
76%
Career Allow Rate
857 granted / 1130 resolved
+5.8% vs TC avg
Strong +15% interview lift
Without
With
+15.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
62 currently pending
Career history
1192
Total Applications
across all art units

Statute-Specific Performance

§101
0.7%
-39.3% vs TC avg
§103
45.6%
+5.6% vs TC avg
§102
35.3%
-4.7% vs TC avg
§112
11.1%
-28.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1130 resolved cases

Office Action

§102 §103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Information Disclosure Statement The information disclosure statements (IDS) submitted on 7/26/23;11/13/25 are in compliance with the provisions of 37 CFR 1.97(b). Accordingly, the IDSs are being considered by the Examiner. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-3, 5-14, 16-19 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Madsen et al. (US 2009/0012208) (“Madsen”). Madsen discloses: (claim 1,13,14) a urinary catheter kit [0162-0163] comprising: an aqueous lubricant composition comprising water and at least one polyether-polyurethane thermogelling copolymer P1, and a urinary catheter with an external coating of thermogelling copolymer P2 comprising at least ether units. (claim 5) the thermogelling copolymer P1 and the thermogelling copolymer P2 comprise polyethylene oxide and polypropylene oxide units. (claim 3) the thermogelling copolymer P2 comprises at least ether units and units selected from urethane units, ester units, and mixtures thereof. [0030,0033], see abstract [0046,0057] Claim 2: the urinary catheter is immersed in the aqueous lubricating composition. [0162-0163] Claim 6,16: the thermogelling copolymer P1 has a polyethylene oxide content of from 50 to 99% (70-95%) by weight based on the total weight of the copolymer. [0104-0105] Claim 7,17: the aqueous lubricant composition comprises from 1 to 20% (2-15%) by dry weight of thermogelling copolymer(s) P1, based on the total weight of the aqueous lubricating composition. [0104-0105] Claim 8,18: the aqueous lubricant composition further comprises glycerin in an amount of from 1 to 30% by weight based on the total weight of the aqueous lubricating composition. [0092,0141] Claim 9,10: the copolymer coating is applied by dipping and drying the catheter in a composition comprising the thermogelling copolymer P2 or by extrusion of a composition comprising said thermogelling copolymer P2. [0136,0152-0154] Claim 11,19: the catheter has two, preferably identical, layers of thermogelling copolymer P2 coating. [0153] Claim 12: the catheter is made of olefinic thermoplastic material, and the olefinic thermoplastic material is previously activated by plasma or previously coated with a primer coat before being coated with the thermogelling copolymer P2. [0046,0137,0155] Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 4, 15 are rejected under 35 U.S.C. 103 as being unpatentable over Madsen. Madsen discloses the invention as substantially claimed but does not directly disclose the viscosity of the thermogelling copolymers. The copolymers comprising polyethylene oxide and polypropylene oxide units is found in Madsen [0030,0033], see abstract [0046,0057]. Thus, the viscosity at 25°C of 5 to 100 mPa.s, (10 to 80 mPa.s) is a known and measurable value to one skilled in the art. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to DEANNA K HALL whose telephone number is (571)272-2819. The examiner can normally be reached M-F 8:30am- 4:30pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kevin Sirmons can be reached at 571-272-4965. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /DEANNA K HALL/Primary Examiner, Art Unit 3783
Read full office action

Prosecution Timeline

Jul 26, 2023
Application Filed
Jan 14, 2026
Non-Final Rejection — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12582799
CATHETER ASSEMBLY
2y 5m to grant Granted Mar 24, 2026
Patent 12576244
FLEXIBLE UNIVERSAL CATHETER SECUREMENT DEVICE
2y 5m to grant Granted Mar 17, 2026
Patent 12575857
Trocar Support
2y 5m to grant Granted Mar 17, 2026
Patent 12564414
METHOD OF SUPRA-AORTIC ACCESS FOR A NEUROVASCULAR PROCEDURE
2y 5m to grant Granted Mar 03, 2026
Patent 12564703
MEDICAL TOOL POSITIONING DEVICES, SYSTEMS, AND METHODS OF USE AND MANUFACTURE
2y 5m to grant Granted Mar 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
76%
Grant Probability
91%
With Interview (+15.2%)
3y 3m
Median Time to Grant
Low
PTA Risk
Based on 1130 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month